Back to Journals » Therapeutics and Clinical Risk Management » Volume 13

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients

Total article views   Abstract views HTML views PDF downloads Totals
6,777 Dovepress* 5,242 890+ 881 6,132
PubMed Central* 0 645 245 645
Totals 5,242 1,535 1,126 6,777
*Since 29 June 2017
+Since July 2016

View citations on PubMed Central and Google Scholar